Multifocal motor neuropathy (MMN) is a rare, purely motor neuropathy. It is a progressive disorder, most patients eventually developing severe fatigue and weakness in the arm muscles that severely impair daily functioning and quality of life. Unlike other motor neuropathies such as motor neurone disease, MMN is treatable with regular infusions of intravenous immunoglobulin (IVIg). Four double-blind, randomised, placebo-controlled studies have shown that in the short term, IVIg significantly improves muscle strength and disability in more than 70 % of patients. The 11 observational studies reviewed in this article confirm that long-term maintenance treatment with IVIg maintains clinical improvement compared to pre-treatment baseline in most patients. Infusions are generally well tolerated, but regular monitoring and re-evaluation of the IVIg maintenance regimen is essential, as most patients need progressive increases in dosage or reduced intervals between infusions to maintain their response to treatment. In the absence of accepted predictive markers, maintenance IVIg should be individualised, based on each patient's initial response, disability and the interval between the first infusion and decline in muscle strength.
Men are more likely than women to be affected, in a ratio of 2.7:1 and are usually diagnosed at an earlier age. 1 Patients with MMN typically present with asymmetrical, predominantly distal limb weakness that follows individual nerves. There is no apparent sensory loss and weakness usually starts in the forearm or hand muscles, though the first symptoms may occur in the distal leg and upper arm. Respiratory and bulbar muscles are unaffected and patients have a normal life expectancy. However, since MMN is a progressive disorder, most patients eventually develop severe fatigue and weakness in the arm muscles, resulting in disability that can seriously impair daily functioning and quality of life.
Unlike other motor neuropathies such as motor neurone disease (MND), MMN is treatable with intravenous immunoglobulin (IVIg). 2 Most patients require regular infusions in order to maintain clinical response and the aim of this review is to consider the effectiveness and safety of long-term or maintenance treatment of MMN with IVIg.
Method
The terms 'multifocal motor neuropathy', 'treatment', 'long term', 'maintenance' and 'IVIg' were used to conduct a PubMed search of articles published in English language journals between 1 January 1980 and 31 December 2011 (see Table 1 ). Papers were excluded if they were single case reports, or were superseded by subsequent publications following up the same group of patients.
Results
The manual search of the results of the PubMed literature search identified a total of 14 studies concerning the long-term or maintenance treatment of MMN with IVIg. Three papers were excluded:
• a case report in one patient; 3 • a publication concerning six patients included in a subsequent, larger study; 4, 5 • and a study of dose titration in patients on maintenance IVIg. 6 The remaining 11 studies listed in Table 2 were included in the analysis. 1, 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] All were retrospective, observational studies, except for one cross-sectional, descriptive study.
Patient Demographics
The 11 studies included a total of 297 patients who, except 10 of them, 15 were treated at centres in Europe. One study of long-term home IVIg treatment included 26 patients with MMN, but did not provide demographic information. 11 Of the 271 patients included in the remaining 10 studies, 1, 5, [7] [8] [9] [10] [12] [13] [14] [15] 183 (67.53 %) were male. Five studies 5, 8, 13, 14 reported the age of onset of MMN: the lowest median age of onset was 36.5 (21-57) years 14 and the highest was 48 (32-59) years.
Nine of the 11 studies reported duration of IVIg treatment. 1, 5, 7, [9] [10] [11] [12] [13] [14] [15] This ranged from a median of nine (2-32) months in eight patients 9 to a mean of 8.1 (1-17) years in 26 patients.
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Intravenous Immunoglobulin Regimen
The initial IVIg dosage regimen was 2 g/kg in two to five days in all studies. Maintenance IVIg dosage and treatment intervals were individualised for each patient, based on their response to treatment and to maintain clinical improvement. 1, 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] Response to Intravenous Immunoglobulin
In the four studies also including treatment-naïve patients, 17 Similarly, plasma exchange may result in the appearance of CB in previously unaffected motor nerves. 18 Immunoadsorption and CSF filtration are also ineffective in most reported patients with MMN.
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A recent Cochrane review noted that there is some evidence that cyclophosamide is effective in MMN when it is used in first-line treatment or when patients do not respond to IVIg. However, its use in maintenance is limited by its potentially significant adverse events, which may be delayed by a number of years. 20 The Cochrane reviewers found little or no robust evidence supporting other, less cytotoxic immunosuppressive agents such as azathioprine, beta interferon, ciclosporin or rituximab. 20 In the only randomised placebo-controlled trial of an immunosuppressive agent in MMN, mycophenolate mofetil did not significantly improve strength or motor function, or reduce the need for IVIg. 21 In contrast, use of IVIg in MMN is supported by evidence from four double-blind, controlled clinical trials. [22] [23] [24] [25] A Cochrane meta-analysis of these short-term trials concluded that, when compared with placebo, treatment with IVIg results in significant improvements in muscle strength and disability in more than 70 % of patients. 2 The studies discussed in this review confirm that, in long-term treatment, IVIg maintains clinical improvement compared with pre-treatment baseline in the majority of patients. However, patients require progressive increases in dosage or reductions in intervals between infusions to maintain this response. As a result, regular monitoring and re-evaluation of the IVIg maintenance regimen are essential.
The mild, gradual decline in muscle strength generally reported in IVIg-treated patients 1, 5, 14 is probably due to continuing axonal degeneration. 26 The single group reporting clinical improvement, as well as re-innervation and significant reduction in CB and axonal
The Long-term Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin degeneration, suggest that their findings may be due to the larger mean IVIg maintenance doses used in their study. 15 However, in the absence of comparative dosing studies or further long-term observational studies, the optimal dose and treatment interval for maintenance IVIg has yet to be established.
CB outside the usual sites of nerve compression is the hallmark of MMN 16 and IgM antibodies against GM1 can be detected in about half of all patients. 27 Some studies have found an association between these objective markers and clinical response to IVIg 5,7,9,12, but other groups have not confirmed these findings. 8, 10, 13 In the absence of accepted predictive markers, the IVIg maintenance regimen should be tailored to each patient based on clinical criteria. These include the patient's initial response to IVIg, their disability and the interval between the first infusion and decline in muscle strength.
It is difficult to investigate the relationship between IVIg dose and response in MMN because of the rarity of the disease and difficulties in randomising the small numbers of patients due to individual variations in affected muscles, paresis, disease duration, age and side effects. 6 However, using the lowest effective IVIg dose and the longest tolerated interval between doses may lead to under-dosing in the long-term. 6 Reduced response to IVIg can be restored in most patients by increasing the dose during the first few years of therapy, but not in longer-term follow-up. 14 
Conclusion
Unlike other motor neurone diseases, MMN is treatable with IVIg. The Long-term Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin
